Rabacfosadine

Rabacfosadine, sold under the brand name Tanovea, is a guanine nucleotide analog used for the treatment of lymphoma in dogs.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Rabacfosadine, sold under the brand name Tanovea, is a guanine nucleotide analog used for the treatment of lymphoma in dogs. It was developed by Gilead Sciences as GS-9219. The active form of rabacfosadine is a chain-terminating inhibitor of the major deoxyribonucleic acid (DNA) polymerases.

In vitro studies have demonstrated that rabacfosadine inhibits DNA synthesis, resulting in S phase arrest and induction of apoptosis. It also inhibits the proliferation of lymphocytes in dogs with naturally occurring lymphoma.

Rabacfosadine was granted conditional approval by the US Food and Drug Administration (FDA) in December 2016, and became the first medication to receive full approval for the treatment of canine lymphoma in July 2021.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1329689708 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.